Zung To is Senior Vice President of Clinical Development. He brings 35 years of industry experience, with more than 20 years in senior leadership roles in early- and late-stage clinical development. His therapeutic expertise spans from immunology to oncology, transplantation, and neuroscience.

Before joining Kezar, Mr. To served as Vice President of Clinical Development Operations, Biometrics, Project Management, and Quality at Kronos Bio. He was also the Hematology Life Cycle Franchise Leader responsible for its franchise long term strategy. Prior to that, he was Vice President of Global Clinical Operations, Data Management, and Strategic Sourcing at Jazz Pharmaceutical. During his tenure at Jazz, he transformed its clinical development infrastructure to accelerate a growing oncology and neuroscience portfolio. Previously, Mr. To spent 14 years at Genentech/Roche in roles of increasing responsibility, including North America Regional Head of Late Stage Oncology Development Operations, and Therapeutic Head of Early Clinical Development . Earlier in his career, Mr. To was a clinical project manager at Abgenix (bought by Amgen) and Syntex Pharmaceuticals (bought by Roche).

He received a B.S in Biological Sciences from University of California, Davis.